USD 893.23 million
Report ID:
SQMIG35I2155 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
60 |
Figures:
75
Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).
The growing prevalence of life-threatening diseases such as cervical cancer, Human Papillomavirus (HPV), HIV, and tuberculosis, has led to an increased demand for adjuvants. These adjuvants play a crucial role in enhancing the efficacy of vaccines against these infectious diseases. Furthermore, there is a rising focus on developing vaccines with long-lasting immunization effects to combat existing and emerging diseases. This emphasis on sustained protection has further fueled the demand for adjuvants in the market. Adjuvant research has become increasingly important in the development of vaccines, as innovative vaccine antigens often exhibit inadequate immunogenicity on their own. The market growth is also attributed to the increasing utilization of recombinant and synthetic vaccines. These advanced vaccines rely on adjuvants to enhance their effectiveness, thereby driving the expansion of the market in the upcoming years. Major players in the industry are actively involved in the discovery and development of new adjuvants to combat fatal diseases. Notably, there are promising products like AS01, ISCOM & ISCOMMATRIX, and AS02 that are currently undergoing clinical trials. The introduction of these pipeline drugs is expected to further propel the market growth. In the United States, a developed country with a significant population and a high influx of travelers, the demand for immunization is substantial. This demand is primarily driven by the need to ensure the safety and well-being of the local population. Moreover, favorable government initiatives aimed at immunizing people against serious diseases are anticipated to contribute to market growth. An example of such an initiative is the program initiated by the National Institute of Allergy and Infectious Diseases, which focuses on advancing the development and utilization of adjuvants for human use.
Global Market Size
USD 893.23 million
Largest Segment
Pathogen-Based Adjuvants
Fastest Growth
Pathogen-Based Adjuvants
Growth Rate
13.99% CAGR
To get more reports on the above market click here to Buy The Report
Global Vaccine Adjuvants Market is segmented by type, route of administration, and region. Based on type, the market can be segmented into pathogen-based adjuvants, and particulate adjuvants. Based on route of administration, the market is segmented into intramuscular route, and intradermal route. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Vaccine Adjuvants Market Analysis by Type
By type, the market can be segmented into pathogen-based adjuvants and particulate adjuvants. Pathogen-based adjuvants refer to the use of whole inactivated pathogens or their components as adjuvants. These adjuvants stimulate a broad immune response by mimicking the natural infection process. Adjuvants derived from bacterial and viral pathogens, such as lipopolysaccharides (LPS), toxoids, and viral proteins, have been extensively used in vaccines for diseases like pertussis, diphtheria, hepatitis B, and influenza. With ongoing research and development efforts, new pathogen-based adjuvants are being explored to improve vaccine effectiveness. This segment is expected to maintain its dominance in the vaccine adjuvants market.
Adjuvant emulsions are oil-based substances that enhance the immune response by providing sustained release and depot effect. Dominated by oil-in-water emulsions, this segment includes well-known adjuvants like MF59® and AS03. Adjuvant emulsions have demonstrated their efficacy in vaccines for diseases like influenza, malaria, and herpes zoster. They are known for promoting a strong and durable immune response. With the increasing demand for vaccine formulations with improved immunogenicity, the adjuvant emulsion segment is expected to witness steady growth.
Vaccine Adjuvants Market Analysis by Route of Administration
By route of administration, the market can be segmented into intramuscular route and intradermal route. The intramuscular route accounted for the largest market share in 2023 due to its ability to provide better immune specificity. This route is commonly used for administering vaccines against HPV, influenza, meningitis, and other diseases. The efficacy of vaccines heavily depends on the route of administration. For example, alum salts, which are widely used as parenteral adjuvants, are ineffective when administered orally or nasally. Therefore, the intramuscular segment dominates the market due to its proven effectiveness in eliciting a robust immune response.
The intradermal route is projected to be the fastest-growing segment in the vaccine adjuvants market. This route offers several advantages, including longer absorption time and duration of action compared to other routes. These factors contribute to increased demand for vaccines administered through the intradermal route. Some adjuvants, such as TLR3-Ligand Poly (I:C), have shown the ability to induce mucosal antibody responses and provide protection against genital HSV-2 infection when administered intradermally. The growing recognition of the intradermal route's potential in enhancing vaccine efficacy drives the rapid growth of this segment.
To get detailed analysis on other segments, Request For Free Sample Report
North America dominated the global vaccine adjuvants market. The United States is a developed country with a substantial population, resulting in a high demand for immunization and vaccine-related products. Additionally, the country experiences a large influx of travelers, which further emphasizes the importance of immunization to ensure public health and safety. Furthermore, the United States has a well-established healthcare infrastructure and favorable government initiatives that support immunization programs, thereby driving the demand for vaccine adjuvants.
On the other hand, the APAC region is witnessing rapid growth in the vaccine adjuvants market. Countries such as China, India, Japan, and South Korea are at the forefront of this growth. APAC is characterized by a large population, increasing disposable incomes, and rising awareness about the importance of immunization. As a result, there is a growing demand for vaccines and vaccine adjuvants to combat infectious diseases. Moreover, governments in the APAC region are taking proactive measures to improve healthcare infrastructure and implement immunization programs, further fueling the market growth. Additionally, the presence of a large number of contract research organizations and manufacturers in countries like China and India contributes to the development and production of vaccine adjuvants in the region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Vaccine Adjuvants Market Drivers
Increasing focus on the development of innovative vaccines against emerging and existing diseases
Vaccine Adjuvants Market Restraints
Complex regulatory landscape surrounding their approval and usage
Request Free Customization of this report to help us to meet your business objectives.
The global vaccine adjuvants market is characterized by a diverse range of companies striving to innovate and meet the growing demand for adjuvant products. Market players are engaged in extensive research and development activities to enhance the effectiveness and safety of adjuvants. Additionally, partnerships, collaborations, and acquisitions are common strategies adopted by companies to strengthen their market position. The competitive environment fosters a continuous drive for technological advancements, improved manufacturing processes, and the development of novel adjuvant formulations, contributing to the overall growth and competitiveness of the market.
Vaccine Adjuvants Market Top Player’s Company Profiles
Vaccine Adjuvants Market Recent Developments
In March 2024, Croda International entered a collaboration agreement with the Access to Advanced Health Institute (AAHI) to innovate and develop vaccine adjuvant formulations.
In February 2024, the United States’ Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks Inc. and SaponiQx, Inc. (a subsidiary of Agenus Inc.) to discover and develop next-generation vaccine adjuvants.
In November 2023, Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global vaccine adjuvants market analysis, the rising prevalence of infectious diseases, including cervical cancer, Human Papillomavirus (HPV), HIV, and tuberculosis, along with the increasing focus on long-lasting immunization against emerging diseases, is boosting the demand for adjuvants. Inadequate immunogenicity of innovative vaccine antigens and the growing use of recombinant and synthetic vaccines further contribute to market growth. Major players are actively involved in the discovery and development of new adjuvants to combat fatal diseases. The market is dominated by North America, particularly the United States, due to its large population, high travel volume, and favorable government initiatives. The Asia-Pacific (APAC) region is experiencing rapid growth driven by a large population, increasing disposable incomes, rising awareness, and government efforts to improve healthcare infrastructure. However, the complex regulatory landscape poses a challenge to the timely introduction of new adjuvants.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 893.23 million |
Market size value in 2031 | USD 2902.45 million |
Growth Rate | 13.99% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Million |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Global Vaccine Adjuvants Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Vaccine Adjuvants Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Vaccine Adjuvants Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Global Vaccine Adjuvants Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35I2155